NDA 201820 · Chiesi
Bethkis
Tobramycin · Inhalation · Aminoglycoside Antibacterial
Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 12, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
144
50 Phase 3, 6 recruiting
FAERS reports
14,537
11,256 serious, 1,372 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 24, 2023.
BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )] . BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV 1 ) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia . ( 1 )
Mechanism: BETHKIS is an aminoglycoside antibacterial [see Clinical Pharmacology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 12, 2012 Original approval · Type 5 - New Formulation or New Manufacturer LabelPediatric Clinical Pharmacology ReviewPediatric Medical Review
1 products under this application
- BETHKIS · TOBRAMYCIN 300MG/4ML · SOLUTION, INHALATION · Prescription · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Ecological Effects of Decolonisation Strategies in Intensive CarePivotal-lookingCompleted
MJM BontenAcademic, hospital or other
NCT02208154 · 8,665 participants · Start Dec 1, 2013 · Primary completion Oct 27, 2017
Drug: Chlorhexidine oral care (CHX-Oro); Selective oropharyngeal decontamination (SOD) and 1 more · For: ICU-ecology (Multidrug Resistant Bacteria); ICU-acquired Bacteraemia
Sites: Edegem, Belgium; Ghent, Belgium; Liège, Belgium · 13 sites in all
- To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic SuspensionPivotal-lookingStatus unknown
Sutphin DrugsIndustry
NCT03975374 · 5,000 participants (planned) · Start Jun 15, 2019 · Primary completion Jul 1, 2019
Drug: Tobramycin/dexamethasone opthalmic solution; Tobradex Opthalmic Solution · For: Blepharo Conjunctivitis
Sites: Jamaica, New York
- Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRAPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT04597008 · 1,660 participants · Start Jun 18, 2021 · Primary completion Jul 30, 2025
Drug: Treatment group; Control group · For: Post Operative Surgical Site Infection
Sites: Birmingham, Alabama; Los Angeles, California; Redwood City, California · 41 sites in all
- Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.Pivotal-lookingRecruiting
University Hospital, LinkoepingAcademic, hospital or other
NCT05169229 · 1,100 participants (planned) · Start Apr 1, 2022 · Primary completion Dec 2028
Drug: Vancomycin + Tobramycin; Saline · For: Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection and 1 more
Sites: Linköping, Sweden
- A Bioequivalence Study of Tobradex AFPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00362895 · 995 participants · Start Apr 2006 · Primary completion Aug 2006
Drug: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension; Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX) · For: Cataract
Sites: Fort Worth, Texas
- Perioperative SDD to Prevent Infectious Complications After EsophagectomyPivotal-lookingRecruiting
Radboud University Medical CenterAcademic, hospital or other
NCT05865743 · 854 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2027
Drug: SDD · For: Esophageal Cancer
Sites: Leuven, Belgium; Nijmegen, Netherlands
- Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract SurgeryPivotal-lookingCompleted
NTC srlIndustry
NCT03739528 · 808 participants · Start Sep 3, 2018 · Primary completion Dec 19, 2018
Drug: Levofloxacin + dexamethasone followed by dexamethasone; Tobramycin + Dexamethasone · For: Cataract
Sites: Ancona, Italy; Altamura, Italy; Bari, Italy · 57 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,324
- pneumonia938
- infective pulmonary exacerbation of cystic fibrosis784
- dyspnoea759
- drug ineffective700
- acute kidney injury688
- death575
- hospitalisation550
- cough534
- cystic fibrosis515
- condition aggravated508
- infection491
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 97 |
| 2006 | 77 |
| 2007 | 124 |
| 2008 | 91 |
| 2009 | 99 |
| 2010 | 101 |
| 2011 | 208 |
| 2012 | 189 |
| 2013 | 165 |
| 2014 | 273 |
| 2015 | 536 |
| 2016 | 696 |
| 2017 | 762 |
| 2018 | 1,328 |
| 2019 | 2,040 |
| 2020 | 1,899 |
| 2021 | 1,145 |
| 2022 | 1,032 |
| 2023 | 871 |
| 2024 | 1,090 |
| 2025 | 947 |
| 2026 | 687 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Bethkis* (Tobramycin*) · HCPCS J7682
2024 spending
$10.2M
Beneficiaries
3,533
10,777 claims
Per beneficiary
$2,874
2024 ASP limit $17.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,304,300 |
| 2021 | $19,742,375 |
| 2022 | $14,068,878 |
| 2023 | $15,144,747 |
| 2024 | $10,153,227 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Aminoglycoside ototoxicity.
Matz GJ · Am J Otolaryngol 1986 · Clinical Trial, Comparative Study
- Topical antibiotics for treating bacterial keratitis: a network meta-analysis.
Song A, Yang Y, Henein C, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
Guan WJ, Xu JF, Luo H, et al. · Chest 2023 · Randomized Controlled Trial, Multicenter Study
- Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis.
Xu F, He LL, Che LQ, et al. · Crit Care 2018 · Review, Network Meta-Analysis
- Efficacy of tobramycin aerosol in nasal polyposis.
Bonfils P, Escabasse V, Coste A, et al. · Eur Ann Otorhinolaryngol Head Neck Dis 2015 · Comparative Study, Multicenter Study
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.